Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes

Journal of Substance Abuse Treatment

Volumn 52, Issue , 2015, Pages 48-57

  Bentzley, Brandon S ^a   Barth, Kelly S ^a   Back, Sudie E ^a   Book, Sarah W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Buprenorphine; Opioid dependence; Provider perspectives, patient perspectives; Treatment cessation

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; NARCOTIC ANALGESIC AGENT;

ARTICLE; DISEASE SEVERITY; DRUG WITHDRAWAL; FOLLOW UP; HEALTH CARE PERSONNEL; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; OPIATE ADDICTION; PATIENT COUNSELING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RESIDENCY EDUCATION; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; OPIOID-RELATED DISORDERS; TREATMENT WITHDRAWAL;

ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; OPIOID-RELATED DISORDERS; WITHHOLDING TREATMENT;

EID: 84925969235     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.12.011     Document Type: Article

References (74)

1. Amass L., Bickel W.K., Higgins S.T., Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases 1994, 13(3):33-45.
2. Amato L., Davoli M., Minozzi S., Ferroni E., Ali R., Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews (Online) 2013, 2:CD003409. 10.1002/14651858.CD003409.pub4.
3. Amato L., Minozzi S., Davoli M., Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews (Online) 2011, 10:CD004147. 10.1002/14651858.CD004147.pub4.
4. Appel P.W., Ellison A.A., Jansky H.K., Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. The American Journal of Drug and Alcohol Abuse 2004, 30(1):129-153. 10.1081/ADA-120029870.
5. Awgu E., Magura S., Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. Journal of Psychoactive Drugs 2010, 42(3):339-346. 10.1080/02791072.2010.10400696.
6. Bailey G.L., Herman D.S., Stein M.D. Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification. Journal of Substance Abuse Treatment 2013, 45(3):302-305. 10.1016/j.jsat.2013.04.002.
7. Barry D.T., Moore B.A., Pantalon M.V., Chawarski M.C., Sullivan L.E., O'Connor P.G., et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine 2007, 22(2):242-245. 10.1007/s11606-006-0050-y.
8. Bates M., Pemberton D.A. The effect of methadone prescribing in a clinic setting on the criminal activity of drug users. Scottish Medical Journal 1996, 41(6):173-175.
9. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics 1988, 43(1):72-78.
10. Breen C.L., Harris S.J., Lintzeris N., Mattick R.P., Hawken L., Bell J., et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 2003, 71(1):49-55. 10.1016/S0376-8716(03)00071-1.
11. Chiang C.N., Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence 2003, 70(2 Suppl.):S39-S47. 10.1016/S0376-8716(03)00058-9.
12. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug and Alcohol Dependence 2008, 94(1-3):151-157. 10.1016/j.drugalcdep.2007.11.003.
13. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., et al. Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction (Abingdon, England) 2011, 106(1):32-51. 10.1111/j.1360-0443.2010.03140.x.
14. Dolan K.A., Shearer J., White B., Zhou J., Kaldor J., Wodak A.D. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction (Abingdon, England) 2005, 100(6):820-828. 10.1111/j.1360-0443.2005.01050.x.
15. Downey K.K., Helmus T.C., Schuster C.R. Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Experimental and Clinical Psychopharmacology 2000, 8(2):176-184. 10.1037//1064-1297.8.2.176.
16. Dreifuss J.A., Griffin M.L., Frost K., Fitzmaurice G.M., Potter J.S., Fiellin D.A., et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence 2013, 131(1-2):112-118. 10.1016/j.drugalcdep.2012.12.010.
17. Dunn K.E., Sigmon S.C., Strain E.C., Heil S.H., Higgins S.T. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Drug and Alcohol Dependence 2011, 119(1-2):1-9. 10.1016/j.drugalcdep.2011.05.033.
18. Egan J.E., Netherland J., Gass J., Finkelstein R., Weiss L. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. Journal of Acquired Immune Deficiency Syndromes 2011, 56(Suppl. 1):S46-S53. B.H.I.V.E.S. Collaborative. 10.1097/QAI.0b013e3182097561.
19. Ekhtiari H., Dezfouli A., Zamanian B., Ghodousi A., Mokri A. Treatment outcome predictors in flexible dose-duration methadone detoxification program. Archives of Iranian Medicine 2013, 16(10):599-601.
20. Feroni I., Peretti-Watel P., Paraponaris A., Masut A., Ronfle E., Mabriez J.-C., et al. French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: Does doctor shopping reflect buprenorphine misuse?. Journal of Addictive Diseases 2005, 24(3):7-22. 10.1300/J069v24n03_02.
21. Fiellin D.A., Barry D.T., Sullivan L.E., Cutter C.J., Moore B.A., O'Connor P.G., et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. The American Journal of Medicine 2013, 126(1):74.e11-74.e17.
22. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. The New England Journal of Medicine 2006, 355(4):365-374. 10.1056/NEJMoa055255.
23. Giacomuzzi S.M., Riemer Y., Ertl M., Kemmler G., Rössler H., Hinterhuber H., et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health-related quality of life assessment. Addiction (Abingdon, England) 2003, 98(5):693-702.
24. Glasper A., Gossop M., de Wet C., Reed L., Bearn J. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. Pharmacology 2008, 81(2):92-96. 10.1159/000109982.
25. Gowing L., Farrell M.F., Bornemann R., Sullivan L.E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews (Online) 2011, 8:CD004145. 10.1002/14651858.CD004145.pub4.
26. Gryczynski J., Mitchell S.G., Jaffe J.H., O'Grady K.E., Olsen Y.K., Schwartz R.P. Leaving buprenorphine treatment: Patients' reasons for cessation of care. Journal of Substance Abuse Treatment 2013, 10.1016/j.jsat.2013.10.004.
27. Guichard A., Lert F., Brodeur J.-M., Richard L. Buprenorphine substitution treatment in France: Drug users' views of the doctor-user relationship. Social Science & Medicine (1982) 2007, 64(12):2578-2593. 10.1016/j.socscimed.2007.02.049.
28. Hillhouse M., Canamar C.P., Doraimani G., Thomas C., Hasson A., Ling W. Participant characteristics and buprenorphine dose. The American Journal of Drug and Alcohol Abuse 2011, 37(5):453-459. 10.3109/00952990.2011.596974.
29. Hillhouse M., Canamar C.P., Ling W. Predictors of outcome after short-term stabilization with buprenorphine. Journal of Substance Abuse Treatment 2013, 44(3):336-342. 10.1016/j.jsat.2012.08.016.
30. Horspool M.J., Seivewright N., Armitage C.J., Mathers N. Post-treatment outcomes of buprenorphine detoxification in community settings: A systematic review. European Addiction Research 2008, 14(4):179-185. 10.1159/000141641.
31. Hser Y.-I., Saxon A.J., Huang D., Hasson A., Thomas C., Hillhouse M., et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction (Abingdon, England) 2013, 10.1111/add.12333.
32. Jaffe J.H., O'Keeffe C. From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence 2003, 70(2 Suppl.):S3-S11. 10.1016/S0376-8716(03)00055-3.
33. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry 1978, 35(4):501-516.
34. Kleber H.D. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues in Clinical Neuroscience 2007, 9(4):455-470.
35. Kleber H.D. Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. JAMA 2008, 300(19):2303-2305. 10.1001/jama.2008.648.
36. Kornør H., Waal H., Ali R.L. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug and Alcohol Review 2006, 25(2):123-130. 10.1080/09595230500537209.
37. Kornør H., Waal H., Sandvik L. Time-limited buprenorphine replacement therapy for opioid dependence: 2-Year follow-up outcomes in relation to programme completion and current agonist therapy status. Drug and Alcohol Review 2007, 26(2):135-141. 10.1080/09595230601146603.
38. Larney S., Gowing L., Mattick R.P., Farrell M., Hall W., Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review 2013, 10.1111/dar.12095.
39. Ling W., Casadonte P., Bigelow G., Kampman K.M., Patkar A., Bailey G.L., et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA 2010, 304(14):1576-1583. 10.1001/jama.2010.1427.
40. Ling W., Hillhouse M., Ang A., Jenkins J., Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction (Abingdon, England) 2013, 108(10):1788-1798. 10.1111/add.12266.
41. Ling W., Hillhouse M., Domier C., Doraimani G., Hunter J., Thomas C., et al. Buprenorphine tapering schedule and illicit opioid use. Addiction (Abingdon, England) 2009, 104(2):256-265. 10.1111/j.1360-0443.2008.02455.x.
42. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews (Online) 2009, 3:CD002209. 10.1002/14651858.CD002209.pub2.
43. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (Online) 2008, 2:CD002207. 10.1002/14651858.CD002207.pub3.
44. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews (Online) 2011, 4:CD001333. 10.1002/14651858.CD001333.pub4.
45. Mitchell S.G., Gryczynski J., Schwartz R.P., O'Grady K.E., Olsen Y.K., Jaffe J.H. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug and Alcohol Dependence 2013, 128(3):222-229. 10.1016/j.drugalcdep.2012.08.027.
46. Mitchell S.G., Morioka R., Reisinger H.S., Peterson J.A., Kelly S.M., Agar M.H., et al. Redefining retention: Recovery from the patient's perspective. Journal of Psychoactive Drugs 2011, 43(2):99-107. 10.1080/02791072.2011.587392.
47. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 2007, 22(4):527-530. 10.1007/s11606-007-0129-0.
48. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. JAMA 1998, 280(22):1936-1943.
49. Newman R.G. Comparing buprenorphine "tapers"-To what end?. Addiction (Abingdon, England) 2009, 104(8). (1428-9- author reply 1429-30). 10.1111/j.1360-0443.2009.02612.x.
50. Nielsen S., Hillhouse M., Thomas C., Hasson A., Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine 2013, 7(1):33-38. 10.1097/ADM.0b013e318277e92e.
51. Nosyk B., Anglin M.D., Brissette S., Kerr T., Marsh D.C., Schackman B.R., et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Affairs (Project Hope) 2013, 32(8):1462-1469. 10.1377/hlthaff.2012.0846.
52. Nosyk B., Guh D.P., Sun H., Oviedo-Joekes E., Brissette S., Marsh D.C., et al. Health related quality of life trajectories of patients in opioid substitution treatment. Drug and Alcohol Dependence 2011, 118(2-3):259-264. 10.1016/j.drugalcdep.2011.04.003.
53. Nosyk B., Sun H., Evans E., Marsh D.C., Anglin M.D., Hser Y.-I., et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study. Addiction (Abingdon, England) 2012, 107(9):1621-1629. 10.1111/j.1360-0443.2012.03870.x.
54. Otiashvili D., Piralishvili G., Sikharulidze Z., Kamkamidze G., Poole S., Woody G.E. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. Drug and Alcohol Dependence 2013, 133(2):376-382. 10.1016/j.drugalcdep.2013.06.024.
55. Ponizovsky A.M., Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. The American Journal of Drug and Alcohol Abuse 2007, 33(5):631-642. 10.1080/00952990701523698.
56. Quaglio G., Pattaro C., Gerra G., Mezzelani P., Montanari L., Jarlais D.C.D., et al. Buprenorphine in maintenance treatment: Experience among Italian physicians in drug addiction centers. American Journal on Addictions 2010, 19(3):222-230. 10.1111/j.1521-0391.2010.00040.x.
57. Rosenthal R.N., Ling W., Casadonte P., Vocci F., Bailey G.L., Kampman K., et al. Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction (Abingdon, England) 2013, 10.1111/add.12315.
58. SAMHSA Medication-assisted treatment for opioid addiction: 2010 State Profiles. Substance Abuse and Mental Health Services Administration 2011, 1-163.
59. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. American Journal on Addictions 2006, 15(3):208-212. 10.1080/10550490600625624.
60. Sigmon S.C., Dunn K.E., Saulsgiver K., Patrick M.E., Badger G.J., Heil S.H., et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry (Chicago, Ill.) 2013, 10.1001/jamapsychiatry.2013.2216.
61. Subramaniam G.A., Warden D., Minhajuddin A., Fishman M.J., Stitzer M.L., Adinoff B., et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011, 50(11):1120-1128. 10.1016/j.jaac.2011.07.010.
62. Suzuki J., Connery H.S., Ellison T.V., Renner J.A. Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. American Journal on Addictions 2014, 10.1111/j.1521-0391.2014.12143.x.
63. Syed Y.Y., Keating G.M. Extended-release intramuscular naltrexone (VIVITROL®): A review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs 2013, 27(10):851-861. 10.1007/s40263-013-0110-x.
64. Thomas C.P., Fullerton C.A., Kim M., Montejano L., Lyman D.R., Dougherty R.H., et al. Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services (Washington, D.C.) 2014, 65(2):158-170. 10.1176/appi.ps.201300256.
65. Tkacz J., Volpicelli J., Un H., Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. Journal of Substance Abuse Treatment 2013, 10.1016/j.jsat.2013.10.014.
66. Tompkins D.A., Smith M.T., Mintzer M.Z., Campbell C.M., Strain E.C. A double-blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. The Journal of Pharmacology and Experimental Therapeutics 2013, 10.1124/jpet.113.209478.
67. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. The Journal of Pharmacology and Experimental Therapeutics 1995, 274(1):361-372.
68. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics 1994, 55(5):569-580.
69. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry 2011, 68(12):1238-1246. 10.1001/archgenpsychiatry.2011.121.
70. Weiss R.D., Potter J.S., Provost S.E., Huang Z., Jacobs P., Hasson A., et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. Contemporary Clinical Trials 2010, 31(2):189-199. 10.1016/j.cct.2010.01.003.
71. Westermeyer J., McCance-Katz E.F. Course and treatment of buprenorphine/naloxone withdrawal: An analysis of case reports. American Journal on Addictions 2012, 21(5):401-403. 10.1111/j.1521-0391.2012.00259.x.
72. Winklbaur B., Jagsch R., Ebner N., Thau K., Fischer G. Quality of life in patients receiving opioid maintenance therapy. A comparative study of slow-release morphine versus methadone treatment. European Addiction Research 2008, 14(2):99-105. 10.1159/000113724.
73. Winstock A.R., Lintzeris N., Lea T. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment. The International Journal on Drug Policy 2011, 22(1):77-81. 10.1016/j.drugpo.2010.08.001.
74. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008, 300(17):2003-2011. 10.1001/jama.2008.574.